Mr. Ford is President of Leadiant Biosciences Ltd. Mr. Ford has more than 30 years of experience in the pharmaceutical industry. He spent the majority of that time with G.D. Searle where he served in a variety of positions including European Finance Director, General Manager of UK Operations, Vice President of Middle East/African Region including subsidiaries in Pakistan and India, Vice President Corporate Licensing/Business Development in the USA, and President of The European Region with a turnover of $800+ million, 18 operating units and 2,500 people. He was a member of the Searle Worldwide Executive Management Team, a $2.5 billion corporation.
His experience spans involvement in strategic alliances, acquisitions, joint ventures, in-licensing, co- marketing/co-development arrangements, product evaluations and strategic and operational reviews.
Dr. Marco Brughera
Dr. Brughera is Group Chief Executive Officer at Leadiant Biosciences S.p.A.
Dr. Brughera has extensive experience in drug development, portfolio optimization, business development and general management particularly in the oncology and rare disease areas across several global pharmaceutical and biotech companies.
He drove the commercial revival of a lead oncology product line resulting in its successful sale to Baxalta and out-licensed the Defibrotide US rights to Jazz Pharmaceuticals. He has extensive track record of discovery, development and registration of products in Oncology, and Rare Disease.
He has held several positions for the Sigma-Tau Group, including Corporate R&D Managing Director.
Marco previously served as Vice President of Preclinical Development at Nerviano Medical Sciences (NMS) and Managing Director at Accellera, an independent CRO with the NMS Group.
He initially held several senior level positions in the areas of research and development with Pharmacia, Pfizer and Farmitalia Carlo Erba.
Dr. Brughera earned his degree in Veterinary Medicine from the University of Milano. He attended Management Courses at Thunderbird American Graduate Business School at Arizona State University and MIT. He was EFPIA deputy topic leader for the ICH review of the Oncology Therapeutic Guidance, publication record includes more 60 publications/communications.
He is currently Board Member of Fennec Pharmaceuticals Inc, Exelead and Naicons. He was previously Board Member at Gentium, Soligenix and Lee’s Pharmaceutical.
Board of Directors Member
Mr. Dini was a strategy and organisation consultant at PricewaterhouseCoopers handling transformational change and organisational design of large companies in many fields like Telecoms, Healthcare, Public Utilities and Government.
Mr. Dini has extensive experience in Pfizer Italy covering a wide range of roles within Marketing and Sales, Strategic Business Planning, Brand Marketing, Customer Marketing and Sales Intelligence and Effectiveness. He earned his degree in economics at Libera Università Internazionale degli Studi Sociali Guido Carli in Rome.
Board of Directors Member
Sanguigni has more than 30 years of experience in key, strategic roles in the pharmaceutical industry. Until February 2016, he served as General Manager of Sigma-Tau Group leading the entire operations of the company.
Within the Sigma-Tau Group he held several top management positions including Chief Executive Officer of Avantgarde S.p.A., Chief Executive Officer of Biosint S.p.A., President of Biofutura S.p.A and Chairman of several European Affiliates.
Raffaele Sanguigni has advanced knowledge and experience in production, logistics, co-marketing and licensing, commercial policies, sales, regulatory, governance and partnering. He graduated with a degree in Agricultural Sciences from the Perugia University.